Introduction
Venous thromboembolism (VTE) is a multifactorial disease and a major cause of morbidity and mortality, defined by multiple interactions between genetic and environmental components. The incidence of VTE in the population is approximately 1 per 1000 per year. 1 Among women in their reproductive age, pregnancy and oral contraceptive (OC) use are the common risk situations of VTE, in spite of the fact that the absolute risk of VTE is less than 1 per 10 000 per year 2 in this part of population. Because the baseline risk of VTE is low in young healthy women, the absolute risk remains low (3-4 VTE per 10 000 women per year using OC). 2 A total of 30% of Czech women in their reproductive age are taking OCs, which is considered as a highly reliable and popular form of contraception. As OCs are so widely used, they contribute to the occurrence of VTE in young women.
A variety of acquired and inherited risk factors interact with OC to increase the risk of VTE. 3, 4 In the Czech population, the prevalence of F IIG20210A is 3% 5 and factor V Leiden (FV Leiden) 2%, 6 but the frequency of other inherited thrombophilia [antithrombin (AT) deficiency, protein C and protein S deficiency] is not precisely known. There is a lack of data on the prevalence of thrombophilic defect and analysis of VTE (mean age at the time of VTE, type of VTE, frequency and type of transient risk factors in the onset of VTE) in young women, who present VTE while taking OC.
In the present study, we have assessed these characteristics in a large cohort of women with VTE on OC use.
Materials and Methods
We analyzed a group of 400 women with VTE in association with OC use seen at our clinic since the beginning of 1997 until the end of 2005. Most of the women come from the East part of Czech Republic. Venous thromboembolism was clinically manifested and objectively documented [Doppler ultrasound, lung perfusion scan, helical computed tomography (CT)] in all cases. None of the women had taken pharmacological thromboprophylaxis [lowmolecular-weight heparin (LMWH) or coumarine] at the time of VTE. We systematically assessed the following characteristics:
1. Mean age at the time of VTE; 2. Duration of OC use till onset of VTE; 3. The frequency of inherited thrombophilia-FV Leiden mutation, F II G20210A mutation, AT deficiency, protein C deficiency, and protein S deficiency. The frequency of hyperhomocysteinemia and APS-presence of lupus anticoagulant (LA), anticardiolipin antibody (ACA), and anti-beta2 glycoprotein I (anti-beta2 GPI) antibodywere also analyzed;
4. The frequency of additional eliciting risk factors for VTE at the time of onset of VTE (immobilization >48 hours, surgery, administration of plaster cast, long travel-by plane more than 6 hours or overnight by bus more than 12 hours, strenuous sport activity, calf injury, arthroscopy); 5. The type of VTE-deep vein thrombosis (DVT)distal, proximal, pulmonary embolism (PE), thrombosis in unusual sites, and so on, as distal thrombosis was considered thrombosis in popliteal vein and lower; 6. The number of thrombosis solely due to the pill and thrombophilia in women before the age of 26 years and above 26 years.
The laboratory thrombophilia workup is precisely described in our article, 7 except for the measurement of homocysteine. Blood samples were collected by venipuncture into plastic tubes containing either 1/10 volume of 3.8% sodium citrate for coagulation assays or 1/10 volume of 0.5 mol/L sodium ethylenediamine tetraacetic acid for DNA extraction after centrifugation (15 min at 2500g) for prothrombin time (PT), activated partial thromboplastin time (aPTT), and AT assays or after double centrifugation (þ10 min at 1500g) for protein C, protein S, and LA assays. Citrated plasma was either analyzed immediately (PT, aPTT, and LA) or stored at À70 C until analyzed (AT, protein C, and protein S). Protein C was determined by coagulation assay using Staclot Protein C (STAGO D, Asniéres, France; normal value, 70%-130%), and in the case of a low value of protein C, a second examination from a new blood sample was carried out and also antigen of protein C was determined by the Asserachrom protein C kit (STAGO D; normal value, 70%-140%) A Staclot Protein S (STAGO; normal value 65%-140%) kit was used for determination of protein S and also, in the case of a low value, the antigen of total protein S and free protein S was evaluated from the second sample by the Asserachrom protein S kit (STAGO D; normal value of total protein S antigen 70%-140%, normal value of free protein S antigen 70%-130%). Antithrombin was determined by chromogenix assay using the Stachrom AT kit (STAGO D; normal value 80%-120%). The normal range for protein C, protein S, and AT was obtained by examination of 100 healthy individuals (50 men, 50 women) from our region, and normal values were compared with the normal range recommended by the manufactures. The diagnosis of APS was made by these tests: To detect LA, the following screening assays were performed: aPTT, PTT Automate (STAGO D); aPTT with high sensitivity to LA, PTT-LA (STAGO D); tissue thromboplastin inhibition test; and diluted Russell's Viper Venom Time. If 1 of these tests was positive, the second determination was performed after 6 to 8 weeks and the test with hexagonal phospholipids (Staclot LA, STAGO D) was carried out for confirmation. A solid-phase immunoassay technique was used to quantify anticardiolipin levels. An IgG level !10 U/mL and an IgM level !7 U/mL were considered positive results, and also in the case of positivity from the first sample, the second evaluation was carried out after 6 to 8 weeks. Anticardiolipin antibodies were tested against the International Standard in IgM and IgG classes. The polymerase chain method was used for FV Leiden and F IIG20210A determination. Genomic DNA was isolated from peripheral blood leukocytes using High Pure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany). The presence of FV Leiden and prothrombin G20210A mutation was determined by the LightCycler 1.5 instrument using commercially available Factor FV Leiden Mutation Detection Kit and Prothrombin (G20210A) Mutation Detection Kit (Roche Diagnostics, Mannheim, Germany). Level of homocysteine was determined immunochemically after l2-hour fasting (normal range 12.5-17 mmol/L) in an analyzer (DPC Immulite 2000). Normal range for homocysteine was obtained by examining 100 healthy individuals (50 men, 50 women) from our region and normal values were also compared with normal range recommended by the manufactures. In all women, the complete thrombophilia workup was done after the cessation of oral anticoagulation therapy, thereby excluding the influence of OC and acute VTE on the results. Only AT deficiency was excluded during the anticoagulation therapy.
The results were statistically assessed (Fisher's exact test, programme NCSS 2004).
Results
Inherited or acquired thrombophilia was diagnosed in 195 (49%) women: FV Leiden mutation in 35%, congenital deficiency of AT in 1.8%, protein C in 0.8%, protein S in 1%, F IIG20210A in 5%, and APS in 5.3% ( Table 1 ). The prevalence of FV Leiden mutation was highly dominant among inherited thrombophilia ( Table 1 ). The combination of FV Leiden with APS was the most frequent among combined thrombophilia ( Table 1 ). Hyperhomocysteinemia has not been found in our investigated cohort. The frequency of inherited thrombophilia in women with VTE solely due to the pill was significantly higher as compared to VTE elicited by the additional risk factor (33.5% vs. 15.25%: P < .0001; Table 1 ). Regarding VTE in unusual sites, 8 women had cerebral vein thrombosis, 2 women had thrombosis in upper extremity, and in 6 women Budd-Chiari syndrome was diagnosed. Concerning thrombosis in unusual sites in association with risk situation, 2 women had cerebral vein thrombosis, 1 in upper extremity and the last woman suffered from Budd-Chiari syndrome.
The distribution of the type of VTE (distal and proximal DVT, PE, or combined DVT/PE) in the subgroup of women with thrombosis solely due to the pill are not different from the subgroup of women with VTE linked to a transient eliciting risk factor ( Table 2 ). Distal vein thrombosis was diagnosed in 231 women (in 110 cases calf thrombosis, in 121 popliteal vein thrombosis). On the other hand, the frequency of PE and thrombosis in unusual sites is higher in the group of VTE without any other triggering factor. Types of transient risk factors were long travel, immobilization, plaster cast, minor and major surgery, or trauma ( Table 2) . Venous thromboembolism was diagnosed within 6 months use of OC in 85 (21%), within 1 year of OC use in 100 (25%), and after more than 1 year use of OC in 300 (75%) women. The prevalence of VTE solely due to the pill was significantly higher (61%) in the group of VTE occurring within 1 year of OC use as compared to the group of VTE occurring after more than 1 year use of OC (Table 3 , P ¼ .0024). The number of thrombosis solely due to the pill and the frequency of thrombophilia in the group of women below and above the mean age of 26 years were not significantly different ( Table 4 , P ¼ .313).
Discussion
Hundreds of millions of women worldwide use OCs. Multiple studies in the 1990 showed that modern ''low-dose'' OC (<50 mg ethinylestradiol) is associated with a 3-fold to 6-fold increased relative risk of VTE (World Health Organization, 1995). 8 The risk is highest during the first year of use, reaching an absolute risk of 12 per 10 000 women per year (for second-generation progesterone-containing OCs), 9, 10 but persists with prolonged use. 9,10 A meta-analysis of studies compared second and third generation of OC, found an overall 1.7-fold increase in risk (3-fold higher risk among the first-time users) 11, 12 and 6-to 9-fold higher risk than the nonusers. 13 All our investigated women took the combined OC, but the precise type is known only in 80% of them. Therefore, we cannot comment on this fact. The precise frequency of use of second and third generation in Czech women is not known as well. Risk of VTE is further increased in the presence of other additional risk factors for VTE, either inherited or acquired. Obesity belongs to one of the most significant risk factor. The combination of obesity and OC is associated with an overall 10-fold increase of thrombotic risk. 14 Unfortunately, body mass index (BMI) is not available from all women and therefore we cannot assess this association. We are aware that it is the most important shortcoming of our study.
A recent case-control study found that the combination of OC and air travel conferred an approximately 14-fold increased risk of VTE, suggesting a multiplicative interaction between these 2 risk factors. 15 Among 14 women with VTE in association with long travel, 13 women traveled overnight by bus and 1 woman had VTE after long haul flight. Contribution of inherited thrombophilia to the onset of VTE in young women is also very substantial. [16] [17] [18] [19] [20] [21] [22] We found high frequency of inherited thrombophilia and APS (49%) in young women (mean age 26 years) with VTE while using OC. A similar high frequency of thrombophilic defects or more than 50% have been reported in women, who presented with an estrogen-related VTE. [16] [17] [18] 23 If we compare the individual types of thrombophilia, we have found similar percentage of FV Leiden (35%: in 32.75% alone and in 2.25% combined with other thrombophilia) as in other previous studies. 16, 17, 24 In these 3 studies, FV Leiden was found in 20% to 35% in the group of women with VTE on OC. Concerning F IIG20210A, we found lower frequency (5%) in comparison with other studies (l4%). 18, 19, 23 Because of the similar prevalence of these gene defects with other parts of Europe, we expected higher prevalence and we did not detect this mutation in any women with VTE in central nervous system (CNS). 25 Combined FV Leiden and F II G20210A in heterozygous form was also found in much lower frequency (0.75%) in comparison with that of Emmerich et al (6%). 20 It is difficult to explain the lower frequency of F IIG20210A mutation in our study group. It can be caused either due to lower prevalence of this mutation in our region (data about prevalence of F IIG20210A are from central Bohemian region) or due to lower gene expressivity of this mutation. Oral contraceptives can result in acquired activated protein C (APC) resistance 26, 27 and therefore in higher risk of VTE.
Among combined thrombophilia, the combination of FV Leiden and APS prevailed (1.5%). Deficiencies of AT, protein C and S were found to be approximately 1%. Because of the low prevalence in the population, the data about the risk in AT, protein C-and S-deficient women are less known and vary between 1% and 4%. 19, 21 Risk of VTE is particularly high in AT-deficient women 22 (28% per year, compared with only 3.4% per year for deficient nonusers). In our 7 AT-deficient women, VTE developed within the first 6 months after introduction of OC and VTE was always proximal and in 4 cases also complicated by PE. Hyperhomocysteinemia and OCs are considered to be relatively weak risk factors for VTE (not for arterial thrombotic event), 28 but in women with cerebral vein thrombosis, it is found in higher frequency [odds ratio (OR) 4.07]. 29 We did not find hyperhomocysteinemia in our cohort (included 10 women with thrombosis in CNS). We do not have the explanation for this result because only a few women took dietary supplements (it is a part of questionnaire). Very low incidence of hyperhomocysteinemia is also found in the individuals with VTE older than 45 years from our region.
In contrast to other study 9 (20-fold higher in the first 6 months, 10-fold higher during the first year), we have not found the inherited or acquired thrombophilia as the significant risk factor for VTE in the first 6 months (and in the first year, respectively) of OC intake. However, the thrombosis solely due to the pill is statistically more prevalent in this period than during the last years. Distal type of VTE highly prevailed in our women without distinction between VTE solely due to the pill and VTE elicited by a transient risk factor.
Conclusion
The high incidence of inherited thrombophilia (43.5%) and APS (5.3%) was found in the cohort of 400 women with VTE in association with OC use. The additional transient risk factors were presented in (43%) FV Leiden, and immobilization of the limb was the most frequent risk factor. The data only confirm the well-known fact that VTE is multifactorial disease.
The results support the screening of a thrombophilia workup in these women and also emphasize the value of proper thromboprophylaxis in risk situations. 
